Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model
Open Access
- 13 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 10 (1), 1-13
- https://doi.org/10.1038/s41467-019-13614-3
Abstract
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease caused by mutations in the ABCB4 gene, resulting in a reduction in biliary phosphatidylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we report results from treating two- or five-week-old Abcb4−/− mice with an AAV vector expressing human ABCB4, resulting in significant decreases of PFIC3 disease biomarkers. All male mice achieved a sustained therapeutic effect up through 12 weeks, but the effect was achieved in only 50% of females. However, two-week-old females receiving a second inoculation three weeks later maintained the therapeutic effect. Upon sacrifice, markers of PFIC3 disease such as, hepatosplenomegaly, biliary phosphatidylcholine and liver histology were significantly improved. Thus, AAV-mediated gene therapy successfully prevented PFIC3 symptoms in a clinically relevant mouse model, representing a step forward in improving potential therapy options for PFIC3 patients.Funding Information
- Vivet Therapeutics.
This publication has 41 references indexed in Scilit:
- Clinical utility gene card for: Progressive familial intrahepatic cholestasis type 3European Journal of Human Genetics, 2013
- Inflammation Promotes the Loss of Adeno-Associated Virus–Mediated Transgene Expression in Mouse LiverGastroenterology, 2011
- RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapyThe Journal of Gene Medicine, 2010
- Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaksProceedings of the National Academy of Sciences of the United States of America, 2010
- Progressive familial intrahepatic cholestasisOrphanet Journal of Rare Diseases, 2009
- Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout MiceMolecular Cancer Research, 2007
- Intrahepatic Injection of Recombinant Adeno-Associated Virus Serotype 2 Overcomes Gender-Related Differences in Liver TransductionHuman Gene Therapy, 2006
- Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genesJournal of Hepatology, 2005
- Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasisJournal of Hepatology, 1997
- Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver diseaseCell, 1993